Key challenges in computational design of peptide therapeutics: From natural ligand reengineering to de novo design
30 Apr 2026
Novel Modalities & Discovery
- On the evolutionary path: What's been done so far in optimizing naturally occurring ligands (GLP-1 drugs are a good example)
- Moving beyond the evolutionary sample: Generative design approaches that can sample novel areas of the design space
- Design for manufacturing scale - Being ready for a global blockbuster
